Keyword: Opdivo

Frances Rena Bahjat, BMS’ former director of in vivo studies, joined Apexigen in a newly created role.

The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.

Jounce shares fall after publication of an ASCO abstract giving initial data from a trial of its first-in-class ICOS inhibitor JTX-2011.

A pilot showed X4’s anti-PD-1 combination spurred activity in patients that didn’t respond to Opdivo treatment alone, with a drug bought from Sanofi.

Management took the action after technical issues slowed progress of the inducible adenoviral vector.

Eli Lilly is acquiring Armo Biosciences and its lead asset, a PEGylated form of the cytokine IL-10, for $1.6 billion.

Incyte is downgrading two pivotal epacadostat-Keytruda trials to phase 2 studies and backing away from six other late-stage tests of its IDO drug.

The studies are the latest dominoes to fall following the failure of Incyte’s rival IDO drug to move the needle in a pivotal trial.

The partners will use Illumina’s NGS capabilities to create IVDs that assess tumor mutation burden and other potentially predictive biomarkers.

Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.